Janssen to Address NICE's Concerns Following Another English Funding No For Spravato

UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.

Target
J&J gets another go with NICE for Spravato • Source: Shutterstock

The UK's National Institute for Health and Care Excellence (NICE) has for the second time recommended against making Janssen's antidepressant spray Spravato (esketamine) available on England's National Health Service. 

NICE initially issued for consultation in January a draft guidance that said it could not recommend the drug for routine use on the NHS for patients with treatment-resistant depression because of uncertainties about the product's clinical and cost effectiveness. In a new 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Health Technology Assessment

More from Market Access